HENAN LINGRUI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.21 CNY | +1.00% |
|
-0.37% | +41.50% |
| 05-13 | Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug | MT |
| 04-25 | Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Strengths
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +41.50% | 1.88B | - | ||
| +26.93% | 5.55B | B- | ||
| -33.55% | 3.52B | C+ | ||
| -3.74% | 3.03B | C | ||
| -26.09% | 2.59B | B- | ||
| -10.93% | 2.28B | - | D+ | |
| +41.84% | 1.46B | - | ||
| -12.94% | 1.43B | - | - | |
| +47.62% | 1.42B | - | ||
| -30.23% | 1.27B | - | - |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
-
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600285 Stock
- Ratings Henan Lingrui Pharmaceutical Co., Ltd.
